



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 346290 COMIRNATY (BNT162b2 [mRNA]) COVID-19 VACCINE 30 micrograms/0.3 mL concentrated suspension for injection vial

ARTG entry for Medicine Registered (Provisional)
Sponsor Pfizer Australia Pty Ltd
Postal Address Level 17 151 Clarence Street, Sydney, NSW, 2000
 Australia
ARTG Start Date 25/01/2021
Product Category Medicine
Status Active
Approval Area Drug Safety Evaluation Branch



Medicine under additional monitoring

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1 . COMIRNATY (BNT162b2 [mRNA]) COVID-19 VACCINE 30 micrograms/0.3 mL concentrated suspension for injection vial

Product Type	Single Medicine Product	Effective Date	21/06/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

Provisionally Registered Indications

COMIRNATY (BNT162b2[mRNA]) COVID-19 Vaccine has provisional approval for the indication below:.,Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 16 years of age and older.,The use of this vaccine should be in accordance with official recommendations.,The decision has been made on the basis of short term efficacy and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.

Provisionally Registered Conditions

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

This product is included in the Black Triangle Scheme

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Vial	Glass Type I Clear	6 Months	Store between minus 60 - minus 90 degrees	Neither child resistant closure nor restricted flow insert	Protect from Light

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Pack Size/Poison information

Pack Size
195 vials

Poison Schedule
(S4) Prescription Only Medicine

Components

1 . COMIRNATY (BNT162b2 [mRNA]) COVID-19 VACCINE 30 micrograms/0.3 mL concentrated suspension for injection vial

Dosage Form Injection, concentrated
Route of Administration Intramuscular
Visual Identification White to off-white frozen liquid.

Active Ingredients

BNT162b2 (mRNA) .5 mg

Other Ingredients (Excipients)

((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
cholesterol
dibasic sodium phosphate dihydrate
distearoylphosphatidylcholine
monobasic potassium phosphate
potassium chloride
sodium chloride
sucrose
water for injections

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary